NCT05087758已完成不适用
An Open-Label Trial to Assess the Clinical Effectiveness of Matrion™ Decellularized Placental Membrane in Subjects With Diabetic Foot Ulcers
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 108
- 试验地点
- 15
- 主要终点
- Wound Healing
研究概览
简要总结
In this study, a novel placental membrane product Matrion™ (LifeNet Health, Inc., Virginia Beach, VA) will be used as a treatment for subjects with diabetic foot ulcers. Matrion is composed of placental membrane derived from donated human birth tissue containing both the innermost amniotic layer and the outermost chorionic layer, inclusive of the trophoblast layer. Matrion is minimally processed and disinfected using a proprietary decellularization technology and terminally sterilized that safely renders the placental membrane acellular and sterile for its intended surgical applications.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •To be considered eligible to participate in the study, a subject must meet the inclusion criteria listed below:
- •Be male or female, between 21 and 80 years of age at the time of consent
- •For subjects with a diagnosis of Type I or Type II diabetes as defined by the American Diabetes Association, have been on a stable anti-diabetic treatment for at least 30 days before the baseline visit
- •Have a full-thickness wound of the lower extremity
- •Have a single target ulcer
- •Have a wound with an area greater than or equal to 1 cm2 and less than 25 cm2 and a depth less than or equal to 9 mm
- •Have a diabetic foot ulcer that has been present for at least 30 days with a Wagner Classification Grade 1 or 2:
- •Grade 1: superficial diabetic ulcer including the full skin thickness but not underlying tissue
- •Grade 2: ulcer extension involving ligament, tendon, joint capsule, or fascia, without presence of abscess of osteomyelitis
- •Have an absence of infection based on Infectious Disease Society of America criteria
- •Have an adequate circulation to the affected lower extremity, defined as at least one these criteria:
- •Transcutaneous oxygen measurement at the dorsum of the foot greater or equal to 30 mmHg
- •Ankle-brachial index (ABI) greater than 0.75
- •At least biphasic Doppler arterial waveforms at the dorsalis pedis and posterior tibial arteries
- •Have the ability to comply with off-loading (if required for specific wound) and dressing change requirements
- •Have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (ICF) approved by an institutional review board (IRB), and agree to abide by the study restrictions and return to the site for the required assessments
- •Have provided written authorization for use and disclosure of protected health information
- •Have a life expectancy of greater than 6 months
排除标准
- •To be eligible for entry into the study, the subject must not meet any of the exclusion criteria listed below:
- •Be pregnant or lactating
- •Have a wound that decreased in size ≥50% between the Screening and Baseline Visits
- •Have circulating hemoglobin A1c exceeding 12% within 90 days of the Screening Visit
- •Have serum creatinine concentrations of 3.0 mg/dL or greater within 30 days prior to screening
- •Have a sensitivity to any of the following antibiotics: Lincomycin, Polymyxin B Sulfate, and/or Vancomycin
- •Have a sensitivity to N-Lauroyl Sarcosinate, and/or Benzonase® or Denarase®
- •Have the wound treated with biomedical or topical growth factors within the previous 30 days before the screening visit
- •Need for any additional concomitant dressing material other than the ones approved for this study
- •Have clinical signs of an infection at the study ulcer site
- •Have the inability to tolerate off-loading (a surgical shoe, removable cast walker or a total contact cast)
- •Have a known or suspected disease of the immune system
- •Have an active or untreated malignancy or active, uncontrolled connective tissue disease
- •Had a treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids less than 30 days before the baseline visit
- •Have presence of necrosis, purulence, or sinus tracts that cannot be removed by debridement
- •Has undergone a revascularization procedure aimed at increasing blood flow in the treatment target limb less than 4 weeks before the baseline visit
- •Have serum aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase levels greater than three times the normal upper limit within 30 days prior to screening
- •Have evidence of active Charcot disease
- •Have undergone treatment with a living skin equivalent within the last 4 weeks before screening
- •Have ongoing evidence of peripheral vascular disease, including greater than one nonpalpable pulse on either foot
- •Have the presence of any condition that in the opinion of the investigator places the subject at undue risk or potentially jeopardizes the quality of the data to be generated
结局指标
主要结局
Wound Healing
时间窗: 12 weeks
Proportion of chronic DFUs that have achieved complete wound closure
次要结局
- Speed of Wound Closure(12 weeks)
- Wound Area(12 weeks)
- Grafts Used(12 weeks)
- Reoccurrence(6 months post termination visit)
- Infection(12 weeks)
- Incidence of Treatment Emergent Adverse Events(12 weeks)
研究者
研究点 (15)
Loading locations...
相似试验
已完成
2 期
An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)AcromegalyNCT03789656Crinetics Pharmaceuticals Inc.47
进行中（未招募）
1 期
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)Neurofibromatosis 1Neurofibroma PlexiformNCT04590235AstraZeneca32
Unknown
2 期
Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®Cystic FibrosisNCT02722122Protalix15
已完成
1 期
CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)Cancer of the BreastTriple Negative Breast CancerER+ Breast CancerBreast CancerMetastatic Breast CancerMale Breast CancerAdvanced Breast CancerNCT02580448Innocrin Pharmaceutical175
已完成
1 期
Tuberculosis Vaccine in Healthy Indian AdultsTuberculosisNCT06438978Bharat Biotech International Limited30